Fosun to Bring Cutting-Edge Cancer Treatment to China

CAR T cell therapy is a type of adoptive cell transfer (ACT) treatment considered to be the “fifth pillar” of cancer treatment, along with drugs, surgery, chemotherapy and radiation. ACT is a form of immunotherapy that collects and uses patients’ own immune cells to treat their cancer. Photo: Visual China

Chinese pharmaceutical giant Shanghai Fosun Pharmaceutical Group Co. Ltd. will launch the cell therapy Yescarta in China, a new variant of a cutting-edge cancer treatment that received its first U.S. regulatory approval just four months ago.

A joint venture between Fosun and Kite Pharma Inc., the U.S. developer of lymphoma treatment Yescarta, has launched an institute in Shanghai to localize the technology and eventually introduce it to the China market, Fosun said in a statement Tuesday.

You've accessed an article available only to subscribers

Try 4 weeks for $0.99

Share this article

Open WeChat and scan the QR code